Quantcast
Last updated on April 18, 2014 at 0:10 EDT

Latest Thiols Stories

2009-10-01 05:30:00

NOVATO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors. He is also CEO of EPISTAT, an international healthcare technology...

2009-09-30 05:30:00

NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger. The combined company is named "Raptor Pharmaceutical Corp." and will commence trading on September 30, 2009 on the NASDAQ Capital Market under the ticker symbol "RPTP." Pursuant to NASDAQ's regulations, for the first 20 trading days the ticker symbol will be...

2009-09-18 13:39:48

The rare genetic disorder cystinosis has been successfully reversed in mice using stem cell transplantation, scientists in California say. The procedure halted the cystine accumulation responsible for the disease and the cascade of cell death that follows, the Scripps Research Institute in La Jolla, Calif., announced in a release Friday. After meeting the children who suffer from this disease, like an 18-year-old who has already had three kidney transplants, our team is committed to moving...

2009-09-15 15:05:00

PALO ALTO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Tuesday, September 22, 2009 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on...

2009-07-16 05:00:00

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of delayed-release cysteamine bitartrate ("DR Cysteamine") for the potential treatment of cystinosis, and its plans for further clinical development of the product candidate, at the Cystinosis Research Network...

2009-07-07 09:20:00

Immunotec Receives NHPD/Health Canada Authorization to Begin a Study on the Effect of the Cysteine-Rich Whey Protein Isolate (Immunocal(R)) in Combination with Physical Exercise on Muscle Function, Body Composition and Inflammatory Cytokine Levels in Elderly Persons: A Randomized, Double-Blind Study. MONTREAL, July 7 /PRNewswire-FirstCall/ - Immunotec Inc. (TSX-V: IMM) announced today that the Natural Health Products Directorate (NHPD) - a division of Health Canada...

2009-07-06 15:32:17

The amino acid N-acetylcysteine appears to reduce symptoms of compulsive hair-pulling in patients with a condition known as trichotillomania, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.Trichotillomania has been described for almost 200 years and researched for more than two decades, but there is currently no approved treatment for the condition, according to background information in the article. "Trichotillomania is...

2009-06-01 11:00:00

NOVATO, Calif., June 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. Under Raptor's...

2009-05-18 11:46:00

NASHVILLE, Tenn., May 18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today the launch of an online in-service program for hospitals using Acetadote (acetylcysteine) Injection, the company's intravenous treatment for acetaminophen overdose. (Photo: http://www.newscom.com/cgi-bin/prnh/20090518/CL18638 ) Available at www.acetadote.net, the webcast provides hospital pharmacists and physicians, educators and other healthcare providers with information and guidelines on dosage and...

2009-04-13 05:30:00

NOVATO, Calif., April 13 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) today announced the appointment of Patrice P. Rioux, M.D., Ph.D., as Chief Medical Officer ("CMO"). Dr. Rioux will be responsible for the clinical and regulatory advancement of Raptor's clinical-stage drug development programs. (Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO ) Raptor's clinical programs include Delayed-Release Cysteamine ("DR...